ARROWHEAD PHARMACEUTICALS, INC.

Key metrics

Financial performance

Over the last 9 fiscal years ARROWHEAD PHARMACEUTICALS, INC.'s revenue grew from $158.33K to $829.45M, a compound annual growth rate of 159.0%. Net profit margin expanded from -51614.6% to -0.2% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,345 filings)

Recent press releases

• Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results2026-05-07

  “Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong footing to continue to drive growth in the near-term with numerous opportunities to create long-term shareholder value,” said Christopher Anzalone , Ph.D., President and CEO at Arrowhead Pharmaceuticals . “We remain focused on a few key areas as being critical sources of sustainable growth for Arrowhead, and we have made tangible advancements across these areas. These include: strengthening our commercial presence to bring REDEMPLO® and potentially other cardiometabolic products in the future to the many patients and physicians who need it; continuing to deliver best-in-class in discovery, development, and regulatory capabilities in support of a deep pipeline of RNAi therapeutics capable of silencing genes expressed throughout the body to treat various diseases; and, being strategic and disciplined around pipeline, portfolio, and financial

Similar companies

The largest companies sharing ARROWHEAD PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).